SCHEDULE 13D: Gabelli Investment Group Discloses 5.02% Stake in Surmodics Inc., Citing Investment for Shareholder Value

A group of investment entities led by Mario Gabelli has disclosed a 5.02% beneficial ownership stake in Surmodics Inc., acquired for investment purposes with a focus on enhancing shareholder value.

Summary

• A group of investment entities, including Gabelli Funds LLC, GAMCO Asset Management Inc., and Gabelli & Co Investment Advisers, Inc., collectively known as the Reporting Persons, have acquired 718,112 shares of Surmodics Inc. common stock.
• This aggregate ownership represents 5.02% of Surmodics Inc.'s 14,295,998 outstanding shares, as reported in the Issuer's most recently filed Form 10-Q for the quarter ended December 31, 2024.
• The total cost for the acquisition of these securities was approximately $23,957,840.
• The largest individual beneficial ownership percentages within the group are held by Gabelli Funds LLC (2.75% or 392,575 shares), Gabelli & Co Investment Advisers, Inc. (1.36% or 194,637 shares), and GAMCO Asset Management Inc. (0.83% or 119,100 shares).
• The Reporting Persons state their intention to hold the securities for investment, continuously analyzing the company's operations, capital structure, and markets.
• While they may suggest changes to operations, management, or capital structure to enhance shareholder value, they do not intend to seek control or participate directly in the management of Surmodics Inc.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A significant investment by a well-known investment group like Gabelli, explicitly for 'investment' and 'enhancing shareholder values,' generally signals a positive outlook on the company's potential. While some sales occurred, the overall aggregate position increased to cross the 5% threshold, indicating a net accumulation and strategic interest.

Positives

• The acquisition of a significant stake by a reputable investment group like Gabelli can signal confidence in Surmodics Inc.'s long-term value and prospects.
• The stated purpose of the investment is to enhance shareholder value, suggesting potential advocacy for strategies beneficial to investors.
• The Reporting Persons' active analysis of the company's operations and capital structure could lead to constructive engagement and improved corporate performance.

Negatives

• The detailed transaction history shows both purchases and sales by different Gabelli entities, indicating varied portfolio management decisions rather than a uniform strong buy signal across all funds.
• Some sales occurred at higher price points (e.g., in January and February 2025) compared to recent purchases (e.g., in March 2025), which could reflect a view on short-term price fluctuations or rebalancing.

Risks

• The Reporting Persons may suggest changes to Surmodics Inc.'s operations, management, or capital structure, which could lead to strategic shifts or potential disagreements with current management.
• While the Reporting Persons do not intend to seek control, their significant stake and stated intent to influence shareholder value could create pressure on the company's strategic direction.
• The investment group's ability to acquire or dispose of additional securities based on their continuous assessment introduces potential volatility in the stock price.

Future Outlook

The Reporting Persons intend to continuously assess Surmodics Inc.'s business, financial condition, results of operations, and prospects. They may acquire additional securities or dispose of existing holdings based on these assessments, their investment objectives, and fiduciary duties. They also reserve the right to suggest or take a position on potential changes in the company's operations, management, or capital structure to enhance shareholder value, though they do not intend to seek control or participate in management.

Management Comments

• "Each of the Reporting Persons has purchased and holds the Securities reported by it for investment for one or more accounts over which it has shared, sole, or both investment and/or voting power, for its own account, or both."
• "The Reporting Persons analyze the operations, capital structure and markets of companies in which they invest, including the Issuer, on a continuous basis... As a result of these analytical activities one or more of the Reporting Persons may issue analysts reports, participate in interviews or hold discussions with third parties, with management or with Directors in which the Reporting Person may suggest or take a position with respect to potential changes in the operations, management or capital structure of such companies as a means of enhancing shareholder values."
• "However, none of the Reporting Persons intends to seek control of the Issuer or participate in the management of the Issuer..."

Industry Context

This filing represents a significant passive investment by a prominent asset management group in Surmodics Inc., a company operating in the medical device and in vitro diagnostics industry. While the filing itself does not detail broader industry trends, such an investment suggests the Gabelli group sees value within this sector or specifically in Surmodics' position within it.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• **Shareholders**: The investment group's focus on enhancing shareholder value could lead to initiatives that benefit all shareholders, such as strategic changes or improved capital allocation. Their potential advocacy for specific corporate governance measures could also impact shareholder rights.
• **Management/Board**: While not seeking control, the significant stake and stated intent to suggest changes could put pressure on Surmodics Inc.'s management and board to consider the Reporting Persons' perspectives and potentially adjust strategic plans.
• **Employees, Customers, Suppliers, Creditors**: Direct impact is not specified, but any strategic changes resulting from the investment group's influence could indirectly affect these stakeholders depending on the nature of those changes (e.g., operational efficiencies, divestitures, acquisitions).

Next Steps

• The Reporting Persons will continuously assess Surmodics Inc.'s business, financial condition, results of operations, and prospects.
• Depending on their assessments, they may acquire additional securities or dispose of all or some of their holdings.
• They may engage in discussions with management or directors and suggest changes to operations, management, or capital structure to enhance shareholder value.
• If the aggregate voting position of all Reporting Persons exceeds 25% of the total voting position of the Issuer, one or more filing persons may transfer voting and/or dispositive power over shares to independent committees of directors or the owners of such shares.

Key Dates

Recommendation

Keywords

Surmodics Inc., Schedule 13D, Beneficial Ownership, Gabelli Funds, GAMCO, Investment Management, Shareholder Value, SEC Filing, Common Stock, Asset Management